Tyra Biosciences
Update in progressTYRA (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on FGFR biology in the United States. It offers SNÅP, a precision medicine platform that guides drug design by generating iterative molecular snapshots to predict genetic changes for oncology and other FGFR3-driven conditions. Its lead candidate, FGFR3, is in trials for metastatic urothelial carcinoma and other solid tumors. TYRA-300 targets skeletal FGFR3-related disorders; TYRA-200 targets intrahepatic cholangiocarcinoma; TYRA-430 targets hepatocellular carcinoma. Founded in 2018, it is headquartered in Carlsbad, California.
Company score
- Sentiment
- 0.14
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.15
- Governance
- 0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.09
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Todd Harris Ph.D.
- Founded2018
- Employees87
- Websitetyra.bio
Identifiers
- ISINUS90240B1061
- FIGIBBG00RCQD9D1
- CUSIP90240B106
- CIK0001863127